Key opinion leaders on GLP-1 receptor agonist clinical trial design

There are more than 50 glucagon-like peptide-1 receptor agonists (GLP-1RAs) in clinical development for Type 2 diabetes, obesity, or both.

Clinical trials on the efficacy and safety of these medicines and combination therapies involving them are ongoing, including cardiovascular outcome trials to prove further safety against cardiovascular events.